← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA4311.0x17.4x21.6x
EV / LTM revenue811.7x2.9x7.3x
Premium to unaffected price11527%41%64%
Premium to 30-day VWAP2433%49%63%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
014282010: 7 deals, 1 clean on every measure201072011: 12 deals, 5 clean on every measure2011122012: 15 deals, 7 clean on every measure2012152013: 13 deals, 8 clean on every measure2013132014: 14 deals, 8 clean on every measure2014142015: 12 deals, 8 clean on every measure2015122016: 7 deals, 5 clean on every measure201672017: 12 deals, 10 clean on every measure2017122018: 14 deals, 4 clean on every measure2018142019: 14 deals, 4 clean on every measure2019142020: 14 deals, 5 clean on every measure2020142021: 15 deals, 7 clean on every measure2021152022: 18 deals, 10 clean on every measure2022182023: 28 deals, 12 clean on every measure2023282024: 17 deals, 9 clean on every measure2024172025: 25 deals, 15 clean on every measure2025252026: 15 deals, 8 clean on every measure202615
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 17.4x median across 43 dealsHealthcare17.4xn=43Materials: 9.7x median across 13 dealsMaterials9.7xn=13
Deals by sector
Healthcare: 252 dealsHealthcare252Materials: 42 dealsMaterials42
Deals by buyer type
Financial sponsor: 5 dealsFinancial sponsor5Strategic: 151 dealsStrategic151Management / founder: 0 dealsManagement / founder0Controlling holder: 1 dealsControlling holder1Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 95 dealsUnclassified95
Deals by enterprise value
Under $250m: 103 dealsUnder $250m103$250m to $1bn: 40 deals$250m to $1bn40$1bn to $5bn: 61 deals$1bn to $5bn61$5bn to $20bn: 40 deals$5bn to $20bn40Over $20bn: 7 dealsOver $20bn7Not computed: 1 dealsNot computed1
Deals by industry code
Chemicals, Pharmaceuticals & Allied Products: 252 dealsChemicals, Pharmaceutic…252Instruments, Medical Devices & Optical Goods: 101 dealsInstruments, Medical De…101Health Services: 84 dealsHealth Services84
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
SteadyMed Ltd.
2018-04-29 · Public merger · $2.63 a share
Held out of the premiums: premium of 168%: distressed or misread
United Therapeutics Corporation
Strategic
Healthcare$43mn.a.39.4x
168%
42% to VWAP
DEFM14A
All cash
Schulman A Inc
2018-02-15 · Public merger · $42.00 a share
A. Schulman, Inc.
Strategic
Healthcare$2.1bn14.6x0.8x
n.a.
DEFM14A
All cash
Impax Laboratories, LLC
2018-02-12 (filed) · Public merger · $18.25 a share
Not named in the filing
Unclassified
Healthcare$2.0bnn.a.2.5x
n.a.
DEFM14A
All cash
Juno Therapeutics, Inc.
2018-01-21 · Take-private · $87.00 a share
Held out of the multiples: EV / LTM revenue 86.8x above 60x
Juno Amended
Strategic
Healthcare$9.7bnn.a.86.8x
28%
SC 13E3
All cash
Juno Therapeutics, Inc.
2018-01-21 · Take-private · $87.00 a share
Held out of the multiples: EV / LTM revenue 86.8x above 60x
Blue Magpie Corporation
Strategic
Healthcare$9.7bnn.a.86.8x
n.a.
SC 13E3
All cash
Biocryst Pharmaceuticals Inc
2018-01-21 · Public merger · $1.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$7mn.a.0.3x
n.a.
DEFM14A
Includes stock
Aceragen, Inc.
2018-01-21 · Public merger · $1.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; EV / LTM revenue 91.4x above 60x
Not named in the filing
Unclassified
Healthcare$82mn.a.91.4x
n.a.
DEFM14A
Includes stock
Biocryst Pharmaceuticals Inc
2018-01-21 · Public merger · $1.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Idera Pharmaceuticals, Inc.
Strategic
Healthcare$7mn.a.0.3x
n.a.
DEFM14A
Includes stock
Aceragen, Inc.
2018-01-21 · Public merger · $1.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; EV / LTM revenue 91.4x above 60x
BioCryst Pharmaceuticals, Inc.
Strategic
Healthcare$82mn.a.91.4x
n.a.
DEFM14A
Includes stock
Sinovac Biotech Ltd
2018-01-05 (filed) · Take-private · $7.00 a share
Not named in the filing
Unclassified
Healthcare$338m6.7x1.9x
23%
SC 13E3
All cash
Lapolla Industries Inc
2017-10-04 · Public merger · $1.03 a share
Icynene U.S. Holding Corp.
Strategic
Healthcare$132m13.6x1.3x
n.a.
DEFM14C
All cash
CALGON CARBON Corp
2017-09-21 · Public merger · $21.50 a share
Kuraray Co., Ltd.
Strategic
Healthcare$1.3bn20.4x2.4x
n.a.
DEFM14A
All cash
Melinta Therapeutics, Inc. /New/
2017-08-08 · Public merger · $0.72 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Cempra, Inc.
Strategic
Healthcare-$137mn.a.n.a.
n.a.
DEFM14A
Includes stock
Patheon N.V.
2017-06-27 (filed) · Public merger · $35.00 a share
Not named in the filing
Unclassified
Healthcare$7.1bn22.2xn.a.
35%
DEFM14A
All cash
Sciclone Pharmaceuticals Inc
2017-06-07 · Public merger · $11.18 a share
Silver Biotech Investment Limited
Financial sponsor
Healthcare$437m11.2x2.6x
11%
DEFM14A
All cash
Alere Inc.
2017-06-06 (filed) · Public merger · $51.00 a share
Abbott Laboratories
Strategic
Healthcare$7.0bn15.6x2.8x
37%
DEFM14A
All cash
Nexvet Biopharma plc
2017-06-02 (filed) · Public merger · $6.72 a share
Not named in the filing
Unclassified
Healthcare$66mn.a.n.a.
n.a.
DEFM14A
All cash
Innocoll Holdings plc
2017-05-11 (filed) · Public merger · $4.90 a share
Not named in the filing
Unclassified
Healthcare$171mn.a.n.a.
n.a.
DEFM14A
All cash
Akorn Inc
2017-04-24 · Public merger · $34.00 a share
Fresenius Kabi AG
Strategic
Healthcare$4.7bn11.8x4.2x
35%
DEFM14A
All cash
Whitehawk Therapeutics, Inc.
2017-03-07 · Public merger · $5.00 a share
Inc.
Strategic
Healthcare$25mn.a.n.a.
n.a.
DEFM14C
All cash
Navidea Biopharmaceuticals, Inc.
2017-02-08 (filed) · Public merger · $0.66 a share
Not named in the filing
Unclassified
Healthcare$101mn.a.4.6x
n.a.
DEFM14A
All cash
Genvec Inc
2017-01-24 · Public merger · $9.14 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; EV / LTM revenue 408.2x above 60x
Intrexon Corporation
Strategic
Healthcare$204mn.a.408.2x
n.a.
DEFM14A
Includes stock
Soleno Therapeutics Inc
2016-12-22 · Public merger · $0.96 a share
Essentialis, Inc.
Strategic
Healthcare$10mn.a.n.a.
n.a.
DEFM14A
All cash
LANXESS Solutions US Inc.
2016-09-25 · Public merger · $33.50 a share
Chemtura Corporation
Strategic
Healthcare$2.4bn18.4x1.4x
n.a.
DEFM14A
All cash
Axiall Corp/de/
2016-06-10 · Public merger · $33.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Westlake Chemical Corporation
Strategic
Healthcare$3.5bnn.a.1.1x
28%
DEFM14A
Includes stock

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More